About this trial
Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV).
This multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.
Eligibility criteria
Qualifiers
Anti-HDV positive
≥18 years old
Sex: m/f/d
Informed consent for prospective procedures
Disqualifiers
Anti-HDV negative
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Hannover Medical School
Lead sponsor
Karolinska University Hospital
Collaborator
Karolinska Institutet
Collaborator
Helmholtz Centre for Infection Research
Collaborator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborator
National Institute of Infectious Diseases Matei Bals
Collaborator